Recent studies showed that Axitinib, a multiple tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, VEGFR3, PDGFR and c-Kit, could improve the anticancer effects of sorafenib in advanced HCC patients [30]. The gene discussed is KDR; the disease is hepatocellular carcinoma.